118K - views

June EMACHMP Committee for Medicinal Products for Human Use CHMP Guideline on

Published bycalandra-battersby

1 10 Comments should be provided using this template The completed comments form should be sent to CVSWPSecretariatemaeuropaeu 11 12 Keywords Obesity weight control guidance 13 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom An agency

Tags : Comments should
Embed :
Pdf Download Link

Download Pdf - The PPT/PDF document " June EMACHMP Committee for Medicinal P..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

June EMACHMP Committee for Medicinal Products for Human Use CHMP Guideline on






Presentation on theme: " June EMACHMP Committee for Medicinal Products for Human Use CHMP Guideline on "— Presentation transcript:

June EMACHMP Committee for Medicinal Products for Human Use CHMP Guideline on - Description

1 10 Comments should be provided using this template The completed comments form should be sent to CVSWPSecretariatemaeuropaeu 11 12 Keywords Obesity weight control guidance 13 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom An agency ID: 4414 Download Pdf

Similar presentations

May EMACHMPBWP Committee for Medicinal Produc ts for Human Use CHMP Guideline on similar biological medicinal products containing biotechnology derived proteins as active substance quality issues re
May EMACHMPBWP Committee for Medicinal Produc ts for Human Use CHMP Guideline on similar biological medicinal products containing biotechnology derived proteins as active substance quality issues re

europaeu Website wwwemaeuropaeu European Medicines Agency 2014 Reproduction is authorised provided the source is ac knowledged Guideline on similar biological medicinal products containing biotechnology derived proteins as active substance quality

April1 EMA/CHMP/281825/20152 Committee for Human Medicinal Products HM
April1 EMA/CHMP/281825/20152 Committee for Human Medicinal Products HM

Adoptedby CHMPfor release for consultation art of public consultation13 May 2015 End of consultation (deadline for comments)November 2015 7 This guideline replaces 'Guideline on clinical devel

22 MayEMA/CHMP/BWP/247713/2012Committee for Medicinal Products for Hum
22 MayEMA/CHMP/BWP/247713/2012Committee for Medicinal Products for Hum

Adoption by CHMP for release for consultation24 May 2012 Start of public consultation31 May 2012 End of consultation (deadline for comments)30 November 2012 Revised draft agreed by BMWP and BWPApril 2

21 February 2013EMA/CHMP/BMWP/652000/2010Committee for Medicinal Produ
21 February 2013EMA/CHMP/BMWP/652000/2010Committee for Medicinal Produ

Adoption by CHMP for release for consultationOctober 2011 End of consultation (deadline for comments)31 March 2012 Agreed by BMWPJanuary Date for coming into effect01 September 2013 Interferon beta,

May Committee of Human Medicinal Products MPQWP Rev
May Committee of Human Medicinal Products MPQWP Rev

03 A greed by uality orking arty 04 May 2012 Rev 03 Adoption by C MP 14 June 2012 Rev 03 Adoption by C MP 21 June 2012 Rev 03 Date for coming into effect 1 October 2012 This guideline replaces guideline CPMPQWP22702 Rev EMEAC VMP13402 Rev2 Keywords

22 May 2013EMA//2013Committee for Medicinal Products for Human Use (CH
22 May 2013EMA//2013Committee for Medicinal Products for Human Use (CH

Adoption by CHMP27 June 2013 Keywords Surface coating, Nanomedicines, non - clinical 7 Westferry Circus Reflection paper on urface coatings: general issues for consideration regarding parenteral admi

GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL
GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL

PRODUCTS INDICATED FOR THE TREATMENT OF PSORIASIS This Guideline is intended to provide guidance for the evaluation of new medicinal products indicated for the treatment of psoriasis. It is intended

About OMICS Group OMICS Group International is an amalgamation of 
About OMICS Group OMICS Group International is an amalgamation of 

Open Access publications.  and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology ‘Open Access’, OMICS Group publishes 400 online open access .

Biosimilars Guideline – a Summary of the Industry Comments
Biosimilars Guideline – a Summary of the Industry Comments

M Bredenhann | Nycomed | 19.11.10. BIOSIMILARS: The Scientific Aspects. BIOSIMILARS: Regulatory Update EU / US. BIOSIMILARS: Summary of Industry . omments. on the MCC Guideline. Discussion Topics.

Codifier of Medicinal Products and Medical Devices for info
Codifier of Medicinal Products and Medical Devices for info

Republci. Jankorozova. M.K.. Head of . MeTA. Secretariat. . 4. th. Forum of . MeTA. Kyrgyzstan. Bishkek, 8 December, 2015. Introduction of 1C Accounting System in healthcare facilities for. 2006-2007.